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Abstract 
Cancer is one of the principal leading causes of death worldwide, and thus it is one of 
the most studied diseases. Animal models have been used during centuries to increase 
human knowledge of these and other diseases. Magnetic Resonance Imaging (MRI) is 
one of most commonly used techniques to retrieve non-invasively anatomical and 
functional information of tumors. Several works have defined the perfusion grade as an 
advantageous indicator for the design of new cancer therapies.  
In this context, it comes up the project presented in this document. Due to the variety of 
protocols find in the literature to study tumor perfusion, the purpose of this project is the 
optimization of two Dynamic Magnetic Resonance Imaging (DMRI) protocols (for 
Dynamic Contrast Enhanced-MRI (DCE-MRI) and Dynamic Susceptibility Contrast 
MRI (DSC-MRI) techniques respectively) to evaluate pancreatic tumor perfusion in 
nude mice. To do that, different DMRI sequences with an administered contrast agent 
were tested. For the optimization of the DCE-MRI two different contrast agent doses 
were tested. And to optimize DSC-MRI protocol two contrast media volumes were 
tested.  
For the evaluation and analysis of the dynamic images obtained three image processing 
programs were employed. One of them was used to evaluate the quality of the images 
obtained. And the other two were employed to obtain quantitative parameters of the 
dynamic images.  
 
Keywords: MRI, tumor, DMRI, DCE-MRI, DSC-MRI, contrast agent. 
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Outline of the document 
The present document is organized in 6 chapters. Chapter 1 presents the motivations of 
this project, and its main objectives. In chapter 2 a brief introduction of the MRI 
physical principles is exposed and also a description about how these images can be 
acquired and processed. Chapter 3 presents the protocols selected and the programs 
employed for the quantification of the images. In chapter 4 the results obtained with the 
image acquisition protocols and the parameters calculated with the software programs 
are exposed objectively. Chapter 5 presents the discussion of the results shown in the 
previous chapter. Finally, in chapter 6 the conclusions of the project and its future 
perspectives are exposed. 
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Chapter 1 
Motivation and Objectives 
 
1.1 Motivation 
Cancer is one of the principal leading causes of death worldwide, and thus one of the 
most studied diseases. To study this and other diseases animal models have been used 
during centuries; in order to increase human knowledge of normal and malfunctioning 
cells, to improve efficacy of chemical compounds for therapy, to test new interventional 
techniques, etc. Animal models allow researchers to discover the underlying basis of 
how and why cancer arise, why primary tumors metastasize, and how various kinds of 
preventive interventions and treatments can be used to stop the progress, growth and 
spread of tumors, and prolong patient lives. Research with animal models using imaging 
and other diagnostic techniques can help in the definition of new treatment strategies 
[1].  
Several works have defined the perfusion grade as an advantageous indicator for the 
design of new cancer therapies, or to develop new studies. A tumor highly perfused is 
synonym of a tumor highly vascularized, and the higher the vascularization, the higher 
the tumor grade (aggressiveness) [2].  
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In this context, it comes up the project “MRI study of tumor vascularization and 
delivery of magnetic nanoparticles” developed by the Unidad de Medicina y Cirugía 
Experimental of the Hospital General Universitario Gregorio Marañón in collaboration 
with the  Stem Cells & Cancer Group of the Centro Nacional de Investigaciones 
Oncológicas (CNIO). The main goal of this project is to deliver multifunctionalised 
magnetic nanoparticles (MNP) in a nude mouse with different types of pancreatic 
tumors implanted (xenograft). These MNP will selectively target to destroy pancreatic 
cancer cells.  
In the mentioned project, the MNP will be tested in different tumors with different 
perfusion grades, Magnetic Resonance Imaging (MRI) will be used to evaluate the 
perfusion of those tumors, and thus the selection and optimization of an MRI protocol 
with that purpose is required. 
There exists an extended and varied literature about MRI protocols to evaluate tumor 
perfusion by using Dynamic Magnetic Resonance Imaging (DMRI), which involves the 
serial acquisition of images during the injection of a contrast agent. However, the 
technique is complex and it is not completely established. Therefore, the necessity to 
determine the optimum protocol for this study. There are two main approaches to 
evaluate DMRI: DCE-MRI and DSC-MRI, both approaches are evaluated in this work. 
 
 
1.2 Objectives 
The main goal of this project is to determine the optimum protocol of DMRI to study 
the perfusion grade of subcutaneous 215 pancreatic tumors. To do that, both DCE-MRI 
and DSC-MRI approaches and different contrast agent concentrations will be tested and 
compared.  
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Chapter 2 
Introduction 
 
The term molecular imaging refers to the set of imaging techniques and processes used 
to produce non-invasive images from inside the body, that give information about the 
structure and the function of these inside parts to help in the detection of possible 
anomalies [3, 4]. These medical imaging modalities are able to detect cellular processes 
at molecular level in vivo, without perturbing the biological system studied.  
Molecular imaging techniques allow to develop imaging systems highly sensitive, 
specific and with amplification methods for complex situations where sensitivity is low 
[3]. The information that these techniques can offer, allows physicians to create a more 
personalized treatment planning for the patient [5].  
In a general way, molecular imaging techniques are based on systems able to detect 
different physical signals emitted by some biological molecules that are imperceptible 
for humans. Once these signals are detected, the system converts them in data that is 
digitalized, and allows the formation of an image. Depending on the imaging technique, 
the information obtained could be structural, functional or both [6]. 
These imaging techniques can be classified according to the type of signal used to create 
the images: techniques based on the employment of ionizing radiation such as X-rays, 
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positron emission tomography (PET), computed tomography (CT), scintigraphy (two-
dimensional images) and single photon-emission computed tomography (SPECT); and 
techniques that used non-ionizing radiation like MRI, ultrasound and optical imaging 
[5].  
Both SPECT and PET are nuclear imaging techniques highly used in clinical for the 
diagnoses of multiple pathologies such as infection (by nuclear labeled leucocytes), 
cancer and myocardial infarct (by Fludeoxyglucose metabolism). Nowadays, due to 
their high sensitivity nuclear imaging is extensively used in preclinical research. 
However, in preclinical settings PET is more employed than SPECT because of its 
higher sensitivity and spatial and temporal resolution. Another imaging technique 
widely employed in clinical and preclinical research is CT; this technique is 
characterized by its high spatial and temporal resolution, contributing to medicine by 
offering a volumetric representation of the body with high diagnostic value. Optical 
imaging is highly extended in biomedical research for in vitro and ex vivo studies due to 
its simplicity and low cost. Finally, MRI technique is able to obtain anatomical, 
functional and even chemical information of the subject study. Besides its good spatial 
resolution (as CT), MRI provides better contrast in soft tissues than other modalities [4]. 
The different types of images that can be acquired with MRI and its excellent properties 
(high spatial and temporal resolution, non-ionizing signal, etc) make it one of the most 
value tools for the diagnostic of tumor lesions in the musculoskeletal system. It is a 
technique that can be used either for the study of anatomical structures or for the 
physiological knowledge [7-9].   
 
 
2.1 MRI physical principles 
Magnetic Resonance (MR) effect was discovered in 1929 by the physician Isidor Isaac 
Rabi [10]; and since its discovery it has continued growing day a day.  
MRI is a complex technique based on the physical phenomenon named nuclear 
magnetic resonance. In general terms, it can be defined as a phenomenon in which 
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certain atomic nucleus (those with non-zero spin values) are able to absorb and emit 
electromagnetic energy at a specific frequency (Larmor frequency) in presence of a 
magnetic field [9]. 
Although several nuclei can be studied with this technique, the most studied one is the 
hydrogen (
1
H), as 
1
H is the most abundant elements in nature and in the human body. 
That is the reason why sometimes MRI literature is referred to protons or spins instead 
of nuclei.  
MRI acquisition is a set of processes where the sample of interest is exposed to an 
external static magnetic field and it is excited with an oscillating magnetic field at a 
specific frequency corresponding to the resonance frequency of the nuclei (RF). The RF 
energy is absorbed by the sample, and after excitation the sample relax emitting RF 
energy, this energy is recorded by a coil. This coil obtains the MR signal that ultimately 
will form the MR images [11]. 
As it can be observed in Figure 1 the MRI signal is a continuous signal; this signal is 
measured and recorded using an analog-to-digital converter (ADC). Once the signal is 
digitized, the MR image can be obtained. The explanation of the details of MRI 
technique is beyond the scope of this project, for further details about MRI physical 
principles the following books can be consulted [9, 12]. 
 
Figure 1. Schematic representation of signal detection [9].  
 
An image to be formed requires more than a single MR signal; thus, it requires more 
than a RF excitation, so, the application of a sequence of different RF pulses and 
magnetic field gradients is needed. This process is known as MRI sequences [9, 13-15]. 
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There exist multiple types of MRI sequences. Some of the most employed are spin-echo 
(SE), inversion recovery (IR) and gradient-echo (GRE) sequences. Depending on the 
image conditions a sequence or another will be used. 
 
2.1.1 Relaxation process 
The process by which nuclei emit the energy absorbed is known as relaxation process. 
This relaxation process is the base for tissue contrast in MRI. Two different relaxation 
processes can be measured in magnetic resonance techniques: T1 and T2.  
 Relaxation T1, also known as spin-lattice relaxation time, is the mechanism by 
which nuclei give up their energy to the surrounding. T1 is defined as a constant of 
time which characterized this process [9, 16]. T1 constant depends on many factors, 
such as the size of molecules of the sample, the nature of those molecules, and the 
existence of macromolecules in the lattice. The molecular motion of nuclei 
(rotational, translational and vibrational) also influences T1 value, affecting to the 
facility (those with short T1 values) or difficulty (large T1 values) nuclei have to 
release their energy [17]. Therefore, T1 is an intrinsic property of each tissue, and it 
produces different intensities in the image for different tissues. 
Those differences in the T1 of tissues can be exploited by applying a T1 weighted 
(T1-w) sequence in MRI [9]. Figure 2A shows an example of a T1-w image of a 
human brain. 
 
 Relaxation T2, also named spin-spin relaxation time, refers to the energy transfer 
from an excited nucleus to another nearby nucleus. This process is characterized by 
the T2 constant [9, 16]. T2 also depends on the nature of molecules of the sample, 
and on its surrounding molecules. Thus, it also can be considered as an intrinsic 
property of each tissue that will affect the facility (short T2 values) or difficulty 
(large T2 values) to decay. As in T1 relaxation time, these differences in magnitude 
will create an image where different tissues will present different intensities and thus 
can be differentiated [9].  
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As in T1, a T2 weighted (T2-w) sequence can be applied to T2 to enhance the 
differences in the T2 of tissues [9]. An example of a T2-w image can be observed in 
Figure 2B. 
 
In an idealized system, T2 relaxation will be affected only by the nature of the 
nuclei. However, in real systems there are small inhomogeneities originated by the 
magnetic field and also by the spin-spin interactions that will also affect T2 
relaxation.  Thus, the real spin-spin relaxation time constant is named T2*, a 
constant that considers both the T2 value of tissue and the effects of the magnetic 
field inhomogeneities 
 
        
 
  
   
 
  
 
 
      
                  
 
Every tissue in human body has its own T1 and T2 values; an example is presented in 
Figure 2, where those intensity differences mentioned before can be observed. In the 
image weighted in T1 (T1-w), tissues with high T1 values, such as cerebrospinal fluid, 
will have lower intensity and will appear darker; and tissues with low T1 values like fat 
will have higher intensity and will appear brighter. While in the T2-w image, tissues 
with high T2 values, such as cerebrospinal fluid, will be represented brighter; and those 
with low T2 values like fat or gray matter will appear darker. 
 A)             B) 
Figure 2 Magnetic resonance images weighted in T1 A), and T2 B) [1]. 
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2.2 Dynamic contrast MRI principles 
The different tissue intensities that MRI offers, allow physicians to diagnose pathologic 
tissues, based on the different relaxation times of healthy and disease tissues. These 
signal differences between normal and pathologic tissue can be enhanced by the 
intravenous administration of a contrast agent.  
Moreover, the employment of a contrast agent with DMRI sequence allows the 
knowledge of the physiology of the sample studied. DMRI involves the serial 
acquisition of images before, during and after the injection of a contrast agent. As the 
contrast agent enters the region under study, it changes T1, T2 or both; and thereby 
alters the MR signal intensity [18]. This fact also enables the tracking of the contrast 
media injected. 
DMRI sequences are highly advantageous tools for tumor diagnostic in the 
musculoskeletal system. The tracking of the contrast agent informs about the 
physiological contrast distribution, which is defined in a time intensity curve (TIC). 
This TIC shows the effect of the contrast in the relaxation times while it passes through 
the vessels (Figure 3). Therefore, a high temporal resolution is required to visualize 
these changes. The analysis of the contrast distribution enables the knowledge of tumor 
vascularization, tissue perfusion and capillary permeability [2, 19].  
 
Figure 3. Time intensity curve after the administration of a contrast agent in a patient with breast cancer 
[8]. 
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There are two different types of dynamic MR sequences: dynamic-contrast-enhanced 
MRI (DCE-MRI) and dynamic-susceptibility-contrast MRI (DSC-MRI). DCE-MRI is 
performed with T1-w images, and DSC-MRI with T2*-w images.  
To obtain dynamic images different MR sequences can be applied (spin-echo, VIBE, 
gradient echo, etc). However, for the analysis of tumor perfusion required in this project 
a gradient echo sequence was selected. This type of sequence is characterized by its 
high sensitivity and its fast MR signal acquisition [8]. Both characteristics are essential 
for tracking the contrast agent to study the tumor perfusion.  
 
2.2.1 Contrast relaxation agents 
As it has been mentioned before, signal differences among tissues can be enhanced by 
the administration of a contrast agent. 
MRI contrast agents are chemical compounds that affect the relaxation times of the 
nuclei presented in the tissue [20], and those relaxation time differences produce 
changes in the intensities between the tissues of the sample. 
The ability of a contrast agent to enhance the nucleus relaxation rate is defined in terms 
of its relaxivity, 
                             
                             
Where     
   are the relaxation rates (R1, R2) without the presence of the contrast agent, 
C is the concentration (molar) of the contrast agent and       are the relaxivity constants 
(T1 and T2) of the agent [21] 
Based on their effect of shortening the T1 or T2 constants, MRI agents can be 
categorized as T1 or T2 contrast agents [20].   
 T1 relaxation agents are formed by one or more paramagnetic metal ions that 
contain one or more unpaired electrons. Its main function is the shortening of T1 
relaxation time of the tissues affected by it, making them to become brighter (higher 
signal). 
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 T2 relaxation agents are typically formed by an agglomerate of iron atoms that 
collectively formed a superparamagnetic center. The use of these agents results in a 
shortening of T2 relaxation time of the tissues. This shortening of T2 affects to the 
signal intensity making it lower, and thus, the image will become darker. 
However, there exists some contrast agents that affects both T1 and T2 relaxation times. 
Some of the most employed ones are based on Gadolinium. In general these contrast 
agents are strongly paramagnetic, stable, effective and low-molecular weight 
complexes. Gadolinium contains seven unpaired electrons and is able to reduce MRI 
relaxation processes producing a decrease in T1 and T2. Thus, it can be used in both 
DCE-MRI and DSC-MRI. Contrast media with Gadolinium has shown no short-term 
toxicity, making it optimal for clinical researches [22]. Therefore, it is an advantageous 
contrast agent since it can be translated without problem from preclinical to clinical 
studies.  
 
2.2.2 DCE-MRI: T1 relaxation 
DCE-MRI is a dynamic technique able to exploit T1 changes caused by the 
administration of a contrast agent. It allows the measurement of permeability and 
perfusion by acquiring images before, during and after the administration of a contrast 
agent. The degree of signal enhancement seen on T1-w is dependent on many factors; 
some of them include tissue perfusion, capillary permeability, the native T1 relaxation 
rates of the tissue and the contrast agent dose [8].  
With this technique, it can be observed the passage of the contrast media intravascularly 
and its leakage in the extravascular space. DCE-MRI is sensitive to the presence of 
contrast medium both within vessels and in the extravascular extracellular space (EES) 
[23, 24]. Besides the intensity changes produced in the blood vessels, in tumors, 
typically 12-45% of the contrast media leaks into the EES during the first pass of the 
contrast [25], this percentage leakage allows to change tumor region relaxation time and 
thus it permits its visualization with a different signal intensity. Once out of the blood 
vessels the contrast agent is free to diffuse within the interstitial space until whole body 
distribution and renal excretion lowers the contrast concentration.  
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2.2.3 DSC-MRI: T2* relaxation 
The second dynamic MRI technique is the DSC-MRI or perfusion-weighted. As DCE-
MRI sequences, DSC-MRI permits to study permeability and perfusion of a certain 
region by continuous acquisition of images before, during and after the injection of a 
contrast agent. In DSC-MRI the changes caused by the contrast agent in T2 relaxation 
are exploited. The degree of signal loss observed is dependent on the vascular 
concentration of the contrast agent and also on the microvessel size and its density [8]. 
The contrast mechanism of this imaging technique is based on the magnetic 
susceptibility properties of the contrast agent that creates local field inhomogeneities 
and thus changes in the T2* relaxation times. The contrast agent leaks through the 
vessel walls into the interstitium, achieving intravascular contrast agent concentration 
high enough to produce variations of the T2* relaxation time and thus to the signal 
intensity of the tissue [23, 26]. 
 
2.2.4 Dynamic imaging in tumors 
It has been highlighted the study of tumor vascularity to know the aggressiveness of the 
tumor [2, 27]. For these studies different techniques can be employed, such as biopsies 
and vascular endothelial growth factors (VEGF). However, these methodologies have 
some drawbacks like the lack of sensitivity (VEGF) and the surgical invasion (biopsy) 
[23].  
Alternatively, some imaging modalities such as MRI, can be used for studying tumor 
structure and physiology in a non-invasively and repeatedly manner. Some of these 
techniques are DCE-MRI and DSC-MRI. DCE-MRI enables to study tumor vasculature 
by measuring perfusion, vascular permeability and blood volume. While DSC-MRI 
allows to measure the blood flow and the blood volume [8, 23].   
Both DMRI techniques differ in their characteristics; some of the most noticeable are 
the phase of the contrast passage studied, or the temporal resolution. DCE-MRI studies 
the contrast passage in both vascular and extravascular space. While, DSC-MRI just 
interrogate the vascular space. Moreover, DCE-MRI possesses a temporal resolution of 
the order of 2-25 seconds. Whilst, DSC-MRI has a temporal resolution of 1-2 seconds 
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for an optimal data acquisition. Although DSC-MRI possesses some limitations, it is 
able to quantify microvasculature changes due to its rapid imaging acquisition [28], and 
the image acquisition follows a relatively simple protocol. Even though DCE-MRI 
requires a more complicated protocol, and it is not able to quantify those 
microvasculature changes since it requires a larger time to carry out an optimal image 
acquisition [8, 26]. A summary of the differences of these and other characteristics of 
both DMRI sequences is presented in Table 1.  
Although both of them are able to evaluate tumors, present literature is contradictory. 
Some authors have categorized DCE-MRI as the general dynamic technique to study 
tumors in regions outside the brain, such as the heart, breast, prostate, etc [29-32]. 
While DSC-MRI has been defined as the standard dynamic technique to study 
intracranial tumors [33, 34]. These classifications have been done because DSC-MRI is 
more difficult to implement when studying extracranial tissues, such as pelvis, due to 
field inhomogeneity effects, and the fact that DSC-MRI standard analysis does not take 
into account extravasation [35]. 
Table 1. Comparison of dynamics MRI techniques [8]. 
 
However, other authors have defined DSC-MRI as a good technique to study tumor 
perfusion regardless of the location [36-39]; since some studies have shown that T2* 
effects are significantly stronger for intravascular contrast agents [40]. Nevertheless, 
other researchers have identified DCE-MRI as the optimal technique to study tumor 
  DSC- MRI DCE-MRI 
Mechanism of tissue 
enhancement 
Susceptibility effects of 
contrast agent on magnetic 
field 
Relaxivity effects of 
contrasts agent on tissue 
water 
Tissue compartment 
being interrogated 
Vascular space Vascular and extravascular 
space 
Tissue signal intensity 
change 
Darkening Enhancement 
Duration of effect and 
optimal data acquisition 
Seconds; 1-2 s Minutes; 2-25 s 
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permeability, for the reason that T1 imaging is not affected by extravasation of the 
contrast agent. Whilst, DSC-MRI technique has as drawback the rapid loss of T2* 
imaging when the contrast agent extravasates in the interstitial space [41, 42]. 
Then with all this contradictory literature, it cannot be clarified which technique is 
better for DMRI [43-47]. Depending on the region of interest may be one is preferred 
according to the characteristics of each of the techniques. But in some situations 
literature has shown that both of them can be practiced (Figure 4) [8, 26, 45-47]. 
As an example of the possibility to employ both dynamic techniques to analyze a single 
region, a study developed in a patient with prostate cancer is presented in Figure 4. 
 
 
Figure 4. Comparison of the T1-weighted DCE-MRI (top) and T2-wieghted DSC-MRI (bottom) data 
collections from a patient with a prostate tumor, by the administration of Gd-DTPA [26].  
 
Figure 4 shows a study where both DMRI imaging modalities have been tested. The 
white arrow of the image, located in the middle, point at the prostate tumor. Images 
situated at the top of the figure were obtained using DCE-MRI. Whilst, images located 
at the bottom of the figure were acquired using DSC-MRI. All images were obtained 
before, during and after contrast agent, as the black arrows of the graph indicate. 
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Focusing on the images obtained with DCE-MRI, it can be observed that as time passes 
after contrast agent administration the tumor becomes brighter. Nevertheless, in the 
images obtained with DSC-MRI occurs the other way around; with the pass of the 
contrast agent the tumor becomes darker [26].  
So, since both methods can be practiced for studying tumor perfusion, and several 
literatures have differed in the use of one technique or other, both DMRI sequences will 
be evaluated in this project and the experimental setup/protocol for each of them will be 
optimized.  
 
 
2.3 Data quantification 
Signal intensity changes produced by the administration of a contrast agent, and the use 
of a DMRI sequence can be assessed qualitatively or quantitatively. Quantitatively they 
can be assessed by using pharmacokinetic model free variables or by the derivation of 
physiological indices using pharmacokinetic models [26].  
Qualitative assessments are based on the shape of the TIC, and they are useful for tissue 
characterization and for assessing response to treatment [26].  
Nevertheless, quantitative analysis aims to directly measure physiological parameters 
such as tissue blood flow, blood volume, interstitial volume or permeability-surface 
area. Depending on the DMRI sequence used for the images acquisition a different post-
processing model will be employed.  
 
2.3.1 DCE-MRI quantification 
Multiple methods have been developed to analyze DCE-MRI data. Some of these 
methods are based on a model (model dependent), although others do not follow a 
defined model (non-model dependent). The use of these methods enables the knowledge 
of the pharmacokinetic parameters, which provide information on blood volume, blood 
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flow, microvessel permeability, contrast media concentration on EES, plasma and 
interstitium [24].  
There are different approaches to analyze DCE-MRI images, such as Tofts, Hoffman, 
and Larsson [26, 48-52]. In this work data analysis was based on a model dependent 
method, Hoffman and on a non-model dependent, the curve parameters method will be 
carried out. Hoffman method is the second the pharmacokinetic model most widely 
applied to characterize murine tumors (the first one is Tofts models) [50]. And it was 
selected since it does not required pre-contrast and post-contrast map images for the 
analysis of the pharmacokinetic parameters [49], making the imaging protocol to be 
faster and simpler (because this method does not require T1 pre-contrast and post-
contrast maps, as Tofts does).  
Hoffman is a two-compartment model based on the linear relationship between MR 
signal enhancement and the contrast agent exchange rates. It is formed by a linear one-
compartment model (central compartment) which represents the concentration of 
contrast media in the plasma; and a peripheral compartment connected to the central one 
by a linear exchange processes in both directions. This peripheral compartment 
represents the extracellular space of the tissue [48, 49]. 
According to the Hoffman model four different quantitative pharmacokinetic 
parameters can be calculated. The contrast agent infusion rate is determined by the 
constant Kin, which influences in the MR signal enhancement. However, the wash-out 
rate of the contrast is determined by other parameter, kel (renal elimination constant). 
The remaining ones parameters k12 and k21 (also known as kep [26]) determine the 
diffusion rate of the contrast between the central compartment and the peripheral one; 
and vice versa. Figure 5 shows a schematic representation of Hoffman model.  
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Figure 5. Schematic representation of the Hoffman model. 
 
Mathematically this model can be described as 
 
      
    
  
         (
             
       
)                 
where S(t) is the MR signal course while the contrast passes, S0 is the MR signal before 
contrast agent injection and A
H
kep is considered an approximate measure of blood 
flow/perfusion of the tumor tissue (A
H
 approximately corresponds to the size of the 
EES) [50]. Thus, with these parameters and equation 2.3, it is possible to analyze the 
tumor perfusion.  
The other method employed in this analysis, the curve parameters, is a model-free semi-
quantitative analysis able to calculate three parameters. The initial area under the curve 
(IAUC) measures the amount of contrast delivered to and retained by the tumor in the 
given time period [53]. The relative contrast enhancement (RCE) defines those regions 
with higher contrast pass. And the last one is the time to maximum enhancement (TTM) 
of the contrast agent [50].  
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2.3.2 DSC-MRI quantification 
The time-activity curve can be modeled by the contrast agent and the signal intensity of 
each pixel  
           
       
                   
where S(t) is the time-activity curve (TAC) for a given pixel, S0 is the baseline signal 
before the contrast agent arrival, ( )mC t  is the measured concentration of contrast agent 
as a function of time and k  is a constant that depends on the scanner and the sequence 
used to acquire the image series. 
By calculating the Arterial Input Function (AIF), which describes the signal intensity 
changes cause by the contrast agent in arteries near the region studied, the concentration 
of the contrast agent (as a function of time) and the idealized contrast bolus; three 
parametric maps can be calculated. The blood volume (BV), blood flow (BF) and the 
mean transit time (MTT).  
 
The BV is defined as 
      
∫     
∫       
                
The expression for MTT is 
 
      
∫    
    
                  
where C(t) is the pass of the contrast agent concentration without the effect of the 
circulatory system (idealized pass of the contrast agent), and Cmax is the maximum of 
C(t) for that voxel. 
Finally, these perfusion variables are related by the central volume theorem equation 
defining BF [24] 
                ⁄                                  
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Knowing all these parametric maps it is possible to study how vascularized and how 
perfused is the tumor. Regions bright in the BF maps are regions with high flux. Also, 
regions brighter in the BV map indicate a bigger amount of blood, which can be 
interpreted as higher vascularized regions.  
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Chapter 3 
Materials and Methods 
 
3.1 Animals 
All animal procedures were approved by the Animal Experimentation Ethics Committee 
of Hospital General Universitario Gregorio Marañón (ES280790000087) and were 
performed according to EU directive (2010/63/UE) and national regulations (RD 
53/2013). All animal manipulation processes have been developed by the co-director of 
the project Lorena Cussó Mula accredited with C category by the Comunidad de 
Madrid.  
Three nude mice with subcutaneous xenograft of 215 pancreatic tumor located in the 
dorsal area, The 215 pancreatic tumors were obtained from patient’s biopsies. 
 
 
 
 
22 
 
3.1.1 Animal preparation 
Mice were anesthetized using 4% sevoflurane in oxygen at 1l/min. After being induced 
to anesthesia, they were placed in a supine position in the bed inside the MRI system, 
with the tumor region close to the coils that would be used for imaging (Figure 6B). 
Sevoflurane 1.5% in 100% oxygen at 3l/min was administered during MR scanning 
process (Figure 6A).  
        
       A)                                                                   B) 
Figure 6. Anesthesia system (A) and position of the mouse (B). 
 
The depth of anaesthesia was monitored by the breathing rate (SA, Instruments). An 
intravenous catheter was inserted into the tail vein of each mouse for contrast agent 
administration. The catheter was connected with an injection line and linked to an 
injection pump (Figure 7A and 7B. Harvard Apparatus PHD 2000, programmable). 
Moreover, animal body temperature was maintained using a forced warm water system 
(Figure 7C. Gaymar) and monitored using a rectal temperature probe (Figure 7C. SA, 
Instruments). 
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                                 A)           B) 
 
 
 
 
 
  
                                                                                                                   C)   
Figure 7. Instrumentation employed for the MR images acquisition. A) Injection pump.              
B) Programmable part of the injection pump. C) 7T MRI system where the black arrows point at the 
warm water system, the green at the rectal temperature motorization, and the red arrow point at the 
breathing rate monitor. 
 
 
3.2 Image acquisition 
MRI images were performed on a small animal 7T MRI system, using a volume coil for 
Tx and an abdominal phased-array coil, with four elements, in RX (BioSpec Bruker, 
Germany). As it has been exposed in Figure 7C. 
For all dynamic images acquisition the order shown below was followed (Figure 8).  
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Figure 8. Diagram showing the imaging protocol for the DMRI images acquisition. 
 
Figure 8 shows the general acquisition protocol for both DCE-MRI and DSC-MRI 
images. First of all, a Tripilot sequence was employed to position the mouse in the 
center of the scanner. Once the animal was placed, a coronal T2-w image was acquired 
to localize the tumor, followed by an axial T2-w sequence. T2-w sequences were 
selected due to its rapid image acquisition and good anatomical definition compared to 
the T1-w sequences. Once the axial image was acquired, the dynamic image was 
planned and performed with the contrast agent administration.  
The parameters and sequences [31, 44, 45] employed in this project were selected after 
a carefully literature review [29, 31, 44, 45, 54-56] 
The contrast agent selected to these studies was gadobutrol (Gadovist ®, Bayer 
Schering Pharma, Berlin, Germany) it is contrast media employer in clinical MRI 
researches that helps to discern healthy tissue from abnormal or injured tissue. To 
evaluate the optimal contrast agent concentration for the DCE-MRI acquisition two 
different contrast dilutions were tested. Firstly, the contrast agent Gadovist (1 mmol/ml) 
was used in a dose of 0.1 mmol/kg body weight, and diluted in a total volume of 0.2 ml. 
After it, the same image acquisition parameters were used but with a different contrast 
dose (0.05 mmol/kg body weight), and it was diluted in a total volume of 0.12 ml.  
In DSC images acquisition also two contrast dilutions were tested to find the optimum 
one. However, in these experiments dose of Gadovist (1 mmol/ml) was maintained (0.5 
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mmol/kg body weight) and just the total volume (dilution) was changed. First, the total 
volume of contrast media of 0.2 ml, and then a volume of 0.12 ml.  
 
3.2.1 DCE-MRI acquisition 
For DCE-MRI studies the diagram showed in Figure 8 was followed. As mentioned, to 
evaluate the optimal contrast agent concentration for this sequence two different 
contrast dilutions of Gadovist were tested. Each of one was evaluated in a different 
animal, since two consecutive acquisitions cannot be performed because some time has 
to pass to eliminate the contrast agent residues.  
For DCE-MRI images, a gradient-echo images were acquired using a Fast Low Angle 
Shot (FLASH) sequence and the following parameters: repetition time (TR) = 78ms, TE 
= 3.5 ms, matrix = 192x192, FoV = 2x4 mm, slice thickness = 1mm, number of 
averages (NA) = 1, number of slices= 8, number of repetitions= 100, and flip angle= 75º 
[44]. 8 images (temporal resolution: 23 s/image) were acquired before the 
administration of the contrast agent. Then, a bolus of 0.2 ml of Gadovist (0.1mmol/kg 
body weight) was injected with a constant rate of 0.2 ml/min [31]. Imaging time was 60 
minutes. 
Then, the same process was repeated in a different mouse maintaining all the DCE-MRI 
sequence parameters and changing the contrast dose: 0.05 mmol/kg body weight diluted 
in a volume of 0.12 ml.  
 
3.2.2 DSC-MRI acquisition 
As in the DCE-MRI, this dynamic imaging acquisition followed the diagram described 
in Figure 8. To obtain these DMRI images same contrast agent used in DCE-MRI was 
employed, in a dose of 0.5mmol/kg body weight [45]. To optimize the Gadovist 
concentration two contrast dilutions were tested too, and just the total volume (dilution) 
was changed from 0.2ml in the first experiment to 0.12 ml in the second one.. In these 
experiments both contrast dilutions were evaluated in the same mouse, but the images 
acquisition were performed in different days, since as it was mentioned before the body 
system needs some time to eliminate the contrast agent residues.  
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After the T2-w images in coronal and axial planes, a single slice of the axial image was 
selected (this technique requires a high temporal resolution due the rapid signal loss 
thus only one slice can be acquired) and the geometry adjusted. Then, the DSC-MRI 
images were acquired with a FLASH sequence. For it the following parameters were 
defined: TR= 5.44 ms, TE= 2.1 ms, flip angle= 15°, slice thickness= 1mm, number of 
repetitions= 300, matrix= 128x128, FoV= 2x4 mm, NA= 2, temporal resolution= 1 
s/image. Before the contrast agent administration 30 images were acquired. After it, a 
bolus of 0.12 ml of Gadovist (0.5 mmol/kg body weight) was injected with a constant 
rate of 2.4 ml/min. The whole process time for acquiring DSC-MRI images was 40 
minutes.  
This process was redone with the same parameters in the same mouse (different day) 
just changing the total volume; now 0.2 ml administered, but maintaining the dose.  
 
 
3.3 Image processing 
Firstly, a qualitative analysis was executed to select the best protocol for each of the 
dynamic techniques; an ImageJ plugin (Dynamic Pixel Inspector) was employed to 
evaluate the quality of those images, this tool measured the intensity values per pixel in 
each image along time.  
Once the best protocol was selected, the images were analyzed quantitatively 
(pharmacokinetic parameters and parametric maps). The images selected to evaluate 
with the programs were acquired from the same mouse, in different days (due to the 
reasons explained before). For their quantitative analysis two different softwares were 
used.  
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3.3.1 DCE-MRI analysis 
To calculate the pharmacokinetic parameters many computer programs can be 
employed. But for the analysis of the data obtained in this project, the software 
application programmed in IDL, DCE@urLAB, developed in the Escuela Técnica 
Superior de Ingenieros de Telecomunicación (ETSIT) was used. It was selected due to 
its open source characteristic [50].  
This tool is able to analyse a region of interest (ROI) within the image data by 
evaluating the contrast agent concentration in that ROI and its effect on T1 relaxation 
time and thus on pixel intensity.  
This software application can analyse the images using five different pharmacokinetic 
models: Tofts [52], Hoffman [49], Larson, curve parameters  and the reference region 
(RR) model. However, as mentioned before for simplicity just two of them were used 
for analysing DCE data: Hoffman and curve parameters models.  
The process described in Figure 9 was followed in order to quantify the DCE-MRI 
images. 
 
Figure 9. Process followed to quantify DCE images with DCE@urLAB software. Step 1 the software is 
opened, image imported and injection frame defined. Step 2 the ROI (tumor) is defined manually. Step 3 
and 4 pharmacokinetic analysis of Hoffman model. Step 3’ and 4’ semi-quantitative analysis using the 
curve parameters model.  
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Firstly, the DCE-MRI images are imported to DCE@urLAB. After it, the injection 
frame is introduced (Figure 9 step 1). Two windows appear (Figure 9 step 2), the left 
one showing the original image (dynamic image); and the right one represents the image 
with a color code to indicate regions with higher contrast pass (RCE). See Figure 10. 
Then, a ROI (new ROI) is defined manually in the tumor region (Figure 9 step 2).  
                    
      A)                                                                      B) 
Figure 10. Dynamic image (A) with a ROI defined, and relative contrast enhancement image (B) 
represented with DCE@urLAB software. 
 
Once the ROI is defined, two pharmacokinetic methods are selected to analyze the 
image (Figure 9 step 3 and 3’). The curve parameters method and Hoffman model. This 
step (Figure 9 step 4 and 4’) is repeated for each of the pharmacokinetic parameters 
(Hoffman: A.kep, A
H
, kep and kel; and Curve parameters:  RCE, IAUC and TTM).  
The scale bar can be adjusted for better tumor visualization (Figure 11).  
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Figure 11. RCE images with different Min and Max values for the color scale. 
 
3.3.2 DSC-MRI analysis 
In the analysis of the set of images acquired by the DSC-MRI technique a plugin of 
open source characteristics of the ImageJ program was used, tool enable to analyse 
these images is LIMPERFUSION-1.0.0 [57]. For the visualization of the DSC-MRI 
parametric maps the software Multimodality WorkStation (MMWKS), developed in the 
Medical Imaging Laboratoryof the Hospital General Universitario Gregorio Marañón 
was used [58].  
The process shown in Figure 12 was followed to analyze the whole image sets of DSC-
MRI. 
 
Figure 12. Order followed to analyze DSC-MRI data. Step 1 images imported to ImageJ. Step 2 LIM 
perfusion plugin is opened. Then, AIF is calculated semi-manually (step 3).Finally, parametric maps are 
obtained (step 4). 
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In order to remove undesired noise it is recommended to remove some frames at the 
beginning and at the end of the image set. Then, LIM Perfusion plugin is opened, and 
the AIF is selected manually (step 3 of Figure 12), by adding the points/pixels that show 
an AIF high and narrow, with an abrupt change (large, early, rapid intensity changes 
[45]; Figure 13). Once selected and accepted the three parametric maps are calculated: 
BV, BF and MTT (step 4 of Figure 12). 
 
                        
       A)                                                                                 B) 
Figure 13. Process to select a good AIF. A) Image analyzed, where the red arrow points at the aorta, 
region where the AIF should be selected. B) Top, example of a right AIF; bottom, example of a wrong 
AIF. 
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Chapter 4 
Results 
 
4.1 DCE-MRI optimization 
The first image exposed in this section was acquired with the DCE protocol and a 
Gadovist dose of 0.1 mmol/kg diluted in a volume of 0.2 ml (Figure 14). 
                                                                               
           A)                                                                   B)  
Figure 14. DCE-MRI images acquired before (A) and after (B) the contrast agent administration; 
contrast dose and volume: 0.1 mmol/kg body weight in 0.2 ml. The white arrow points the tumor 
localization. 
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Figure 14 shows how the tumor becomes brighter once the contrast agent had been 
injected (Figure 14B). Before the contrast agent (Figure 14A) the tumor just is bright at 
its surroundings. While after the contrast media administration tumor becomes brighter 
at its surroundings but also inside it. Both images are shown with the same window-
level. 
These changes caused by the effect of the contrast agent in the relaxivity times of the 
tissues can also be seen with a color code bar in Figure 15. These images were 
represented using the Fire option of the ImageJ program, for a better appreciation of the 
intensity changes. In Figure 15B, it can be observed how the tumor becomes 
orange/yellow compared to Figure 15A. These changes in color represents the contrast 
pass and the effect caused by the DCE protocol, indicating the areas with more contrast 
pass (higher intensity value) orange/yellow, brighter; and the area with less contrast 
pass and enhancement blue/purple, those more darker (less intensity values).  
                    
A)                                                                  B) 
Figure 15. DCE-MRI images acquired before (A) and after (B) the contrast agent administration using 
the Fire option of ImageJ, contrast dose and volume: 0.1 mmol/kg body weight in 0.2 ml. 
 
The image quality was evaluated with the Dynamic Pixel Inspector plugin, and Figure 
16 represents the results obtained. This plot indicates the intensity level of a selected 
pixel inside the tumor across time. It can be observed that after the injection of the 
contrast media intensity decreases (T2 effect), while it should increase due to the T1 
effect of the contrast agent.  
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Figure 16. Dynamic Pixel Inspector analysis of DCE-MRI images with a Gadovist dose of 0.1 mmol/kg 
body weight diluted in 0.2 ml. 
 
Images shown in Figure 17 were acquired using the same image protocol of Figure 14 
(DCE image acquisition protocol) but in a different mouse, with different contrast dose 
and volume dilution (0.05 mmol/kg body weight and 0.12 ml respectively). Figure 17A 
was acquired before contrast agent injection and Figure 17 B, after it. It can be seen that 
in the tumor some changes occurred in the intensity (in the relaxivity of the tissues) 
during the contrast pass. Before the contrast administration the tumor presents a darker 
color while once the contrast agent passed, the tumor became brighter. Both images 
have the same window-level. 
                                                                                  
A)                                                                    B) 
Figure 17. DCE-MRI images acquired before (A) and after (B) the contrast agent administration; 
contrast dose and volume: 0.05 mmol/kg body weight in 0.12 ml. The white arrow points the tumor 
localization. 
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To visualize those changes easily, the Fire option of ImageJ was applied (Figure 18). 
Before the administration the tumor is represented with a purple tone, and after it the 
tumor is stained with a pinker color-scheme.  
                              
A)                                                                      B) 
Figure 18. DCE-MRI images acquired before (A) and after (B) the contrast agent administration using 
the Fire option of ImageJ. Gadovist dose 0.05 mmol/kg body weight, and diluted in 0.12 ml.   
 
In Figure 19 it is presented the results obtained with the Dynamic Pixel Inspector tool in 
a region of the tumor. It was corroborated that after the contrast agent administration 
only T1 effect appeared in the tumor; the intensity values increased after the injection of 
the contrast media. Any T2 effect was noticeable.   
 
Figure 19. Dynamic Pixel Inspector analysis of DCE-MRI images with a Gadovist dose of 0.05 mmol/kg 
body weight diluted in 0.12 ml. 
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4.2 DSC-MRI optimization 
Results obtained with the DSC image acquisition protocol are represented in the 
following figures. Figure 20 exposes the images acquired with the DSC-MRI protocol 
and a contrast volume of 0.12 ml.  
                                                                              
A)                                                                      B) 
Figure 20. DSC-MRI images acquired before (A) and after (B) the contrast agent administration; 
contrast agent volume 0.12 ml. The white arrow points the tumor localization. 
 
In Figure 20 it can be observed that the tumor does not show significant changes in 
intensity before and after the contrast agent administration (both images have the same 
window-level.). As in the rest of the images, the Fire option was applied in these images 
to observe contrast enhancement with a different color code (Figure 21).  
                        
A)                                                                B) 
Figure 21. DSC-MRI images acquired before (pre-contrast image; A) and after (post-contrast image; B) 
the contrast agent administration using the Fire option of ImageJ. Contrast agent volume 0.12 ml. 
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As in Figure 20, no relevant changes in the color-scheme of the tumor are observed. 
This lack of change was confirmed by using the Dynamic Pixel Inspector plugin (Figure 
22). 
 
Figure 22. Dynamic Pixel Inspector analysis of DSC-MRI images with a contrast media of 0.12 ml 
 
The next set of images (Figure 23 represents the DSC images acquired with the same 
protocol as in Figure 20, but with a different contrast agent volume (0.2 ml). It can be 
observed how the intensity levels changed after the administration of the contrast agent. 
By looking at the tumor region, it can be seen that before the contrast injection the 
tumor was brighter. Whilst, when the contrast was injected the tumor became darker. 
This darkening was caused by the changes in the relaxivity times of the tissues, which 
provoked a decreased in the intensity levels. 
                                                                              
A)                                                                B) 
Figure 23. DSC-MRI images acquired before (pre-contrast image; A) and after (post-contrast image; B) 
the contrast agent administration; contrast agent volume 0.2 ml. The white arrow points the tumor 
localization. 
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Both images have the same window-level (Figure 23). As in the rest of images, the Fire 
option was applied to observe these contrast changes with a color code (Figure 24). It 
can be observed contrast agent affects to the intensity levels changing from an 
orange/yellow color-scheme to a pink/purple tone.  
                  
A)                                                                  B) 
Figure 24. DSC-MRI images acquired before (pre-contrast image; A) and after (post-contrast image; B) 
the contrast agent administration using the Fire option of ImageJ. Contrast agent volume 0.2 ml. 
 
This darkening is confirmed by the used of the Dynamic Pixel Inspector plugin, Figure 
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Figure 25. Dynamic Pixel Inspector analysis of DSC-MRI images with a contrast media of 0.2 ml 
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4.3 Quantitative analysis 
In the previous section it was seen that only one of the protocols in each case gave 
optimal results. These optimized protocols were (DCE and DSC) analyzed 
quantitatively using the quantification methods explained before (Section 3.3 Image 
processing). As it was mentioned, in this case, the images compared were obtained from 
the same mouse in different days which explains the different tumor locations in the 
images. 
 
4.3.1 DCE-MRI quantification 
Images acquired with the only successful DCE-MRI protocol (0.05 mmol/kg body 
weight diluted in 0.12 ml) were analysed with the DCE@urLAB program following the 
processes defined in Figure 9. As the figure shows, two different methods were 
employed in this analysis (curve parameters and Hoffman model).  
Figure 26 presents the original image with the tumor selected as the ROI, where 
parameters were calculated. 
 
Figure 26. Original DCE-MRI image with the ROI selected for the quantification analysis. 
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In the next set of images (Figure 27) the pharmacokinetic parameters (A.kep, A
H
, kep and 
kel) obtained using the Hoffman model are exposed. All the images present each own 
color-scale with their maximum and minimum values.  
                      
A)                                                                    B) 
 
                         
    C)                                                                  D) 
Figure 27. Pharmacokinetic parameters of the Hoffman model in the ROI (tumor) of DCE-MRI images. 
A) A.kep; B) kep; C) A
H
; and D) kel 
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In Figure 27A Akep measured in min
-1
 can be observed, where the higher values 
(according to the color-scheme bar) of this constant are at the left-top region of the 
tumor. Thus, this region is characterized by its higher values of blood flow/perfusion. 
Figure 27B exposed the different values of kep (unit min
-1
) parameter of the ROI, in 
general there are medium values (between 0.02-0.04), and the higher ones can be find in 
the surroundings of the upper part of the tumor and some of them in the center. Figure 
27C displays the A
H
 (size of the EES) parameter, which presents higher values in the 
left zone of the ROI (according to the color-scheme bar). Finally, Figure 27D represents 
the kel (min
-1
, elimination rate of the contrast agent), and it can be seen that the left-top 
region shows higher elimination rate (around 50 min
-1
).  
The results obtained in the analysis of the curve parameters model (IAUC, RCE and 
TTM) are shown in Figure 28. The IAUC parameter is shown in Figure 28A, in general, 
the whole tumor presents high values (higher ones, close to 5, at the top-left of the ROI) 
of IAUC. The same occurs with the RCE parameter, in Figure 28B it can be seen that 
the whole tumor has high values of RCE (between 100 and150). This indicates that the 
whole tumor is a region with high contrast enhancement. Finally, Figure 28C shows the 
TTM of the tumor, indicating the bottom of the ROI as a region with high values.  
     
A)                                            B)                                          C) 
Figure 28. Parameters of the curve parameters model in the ROI (tumor) of DCE-MRI images. A) IAUC; 
B) RCE; and C) TTM. 
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4.3.2 DSC-MRI quantification 
The DSC protocol selected with one of the contrast volume (0.2 ml of contrast media) 
was analysed with the LIMPERFUSION- 1.0.0 plugin of the ImageJ program. Three 
parametric maps were obtained for each dynamic image: BV, BF and MTT.  
Figure 29 shows two DSC images acquired before (Figure 29A) and after (Figure 29B) 
the contrast agent administration. In both of them it the intensity changes (decrease in 
the intensity values) in the tumor region (located at the bottom- right area of the image) 
occasioned by the contrast media can be observed.  
                    
A)                                                                     B) 
Figure 29. DSC-MRI images acquired before (pre-contrast image; A) and after (post-contrast image;    
B) the contrast agent administration; contrast agent volume 0.2 ml. 
 
Figure 30 represents the BV parametric map. Where Figure 30A represents the BV map 
in the original scale (grays) and the other one presents the same image with a red-blue 
color scheme obtained with the MMWKS program, Figure 30B. In all the images of 
Figure 30 it can be observed the regions with higher BV, according to the different 
color-schemes used. Figure 30A shows brighter the tumor region, which means that 
inside of the tumor is a higher BV value compared with the rest of the tumor Figure 30B 
shows the same results in the different color scale, a yellow/orange tone (values 
between 0.57-1.48).  
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      A)                                                                  B) 
Figure 30. BV parametric map represented in two color scales. A) Grays. B) MMWKS program (red-blue 
color scheme).  
 
Figure 31 defines the BF parametric map, where the areas with higher BF are 
represented brighter (gray levels, Figure 31A), yellow/orange (red-blue color scheme 
obtained in the MMWKS program, Figure 31B).  
                                                                                   
   
 
 
 
 
 
 
      A)                                                                      B) 
Figure 31. BF parametric map represented in different color scales. A) Grays. B) MMWKS program 
(red-blue color scheme). 
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In the following image (Figure 32) the MTT parametric map is shown. In the image, the 
areas more homogenized are the areas with similar MTT value, which means areas with 
similar BV/BF ratio. These similar values can be corroborated looking at Figure 30 and 
Figure 31. 
                                                                             
     A)                                                                     B) 
Figure 32. MTT parametric map represented in the gray scale (A), and in the red-blue color scheme 
acquired with the MMWKS (B). 
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Chapter 5 
Discussion  
 
In this project two protocols for dynamic imaging acquisition to analyze pancreatic 
tumor perfusion in mice have been optimized, one for DCE-MRI and the other one for 
DSC-MRI.  
As it was mentioned before, the image protocol was selected based on the literature [31, 
44, 45]. To optimize the DCE-MRI protocol two different contrast doses of Gadovist 
were tested in two different mice: 0.1 mmol/kg body weight diluted in 0.2 ml in one 
mouse, and 0.05 mmol/kg body weight diluted in 0.12 ml in the other mouse. While the 
optimization of DSC-MRI protocol was achieved by testing two different contrast 
media volumes (keeping constant the Gadovist dosage): 0.2 and 0.12 ml in the same 
mouse, but not in consecutive acquisitions.  
Once the protocols with proper behavior were assessed, Gadovist dilution 0.05 mmol/kg 
in 0.12 ml for DCE-MRI and Gadovist 0.5 mmol/kg diluted in 0.2 ml for DSC-MRI, the 
dynamic images were analyzed with DCE@urLAB and LIMPERFUSION 1.0.0 
programs. Pharmacokinetic parameters of DCE-MRI and parametric maps of DSC-MRI 
enable the knowledge of the tumor perfusions, concretely Akep and BV [46, 50]. 
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5.1 DCE-MRI optimization 
Results obtained with both contrast agent administration rates, shown in Figure 14 and 
Figure 17, have demonstrated that the optimal contrast dose and volume was 0.05 
mmol/kg body weight and 0.12 ml respectively.  
In the case of the 0.1 mmol/kg dose, despite some brightening can be observed after the 
administration of the contrast agent, the results obtained with the Dynamic Pixel 
Inspector plugin (Figure 16) indicated some T2 effects in the image, since the intensity 
values decayed after the contrast agent administration. So this dose was discarded. 
Some authors have mentioned that the contribution of T2 effects can be minimized by 
using a more diluted contrast agent solution [34]. This was confirmed with the results 
obtained by lowering the dose (0.05 mmol/kg body weight diluted in 0.12 ml). The 
results obtained with this Gadovist dose (Figure 17) indicate a brightening of the tumor 
region after the contrast passed. Moreover, the intensity-frame graph (Figure 19) 
acquired with the Dynamic Pixel Inspector demonstrates that the contrast agent has not 
effect on T2 relaxivity values.  
So, results have verified that the protocol selected for DCE-MRI images acquisition 
with a 0.05 mmol/kg body weight diluted in 0.12 ml was optimal to study pancreatic 
tumor  
 
 
5.2 DSC-MRI optimization 
Two different protocols for the optimization of DSC-MRI image acquisition were tested 
(Figure 20 and Figure 23 shows the results obtained). As in the DCE-MRI experiments, 
the MRI parameters were maintained in both analysis, but contrast agent volume was 
changed (keeping constant the dose of Gadovist). The two contrast agent volume (0.2 
ml and 0.12 ml) indicated different results in the pre and post-contrast images. Just the 
contrast volume of 0.2 ml showed intensity values changes after the contrast pass 
(Figure 23).  
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No intensity changes were observed after the contrast injection Figure 22 for the first 
volume tested. This indicates that maybe a bolus of that volume is not enough to reach 
the tumor region or to perfuse it. Maybe a higher volume is required to perfuse the 
tumor region and to be “captured” by the coil of the MR system.  
Therefore, the results obtained in the 0.2 ml contrast media have verified the optimal 
protocol for the acquisition of DSC-MRI images, and thus for its analysis (parametric 
maps BV, BF and MTT) to study pancreatic tumor perfusion (Figure 30, Figure 31 and 
Figure 32). 
 
 
5.3 DCE and DSC: comparative 
Images obtained (belonging to the same mouse) with the protocols selected explained 
before were analysed. DCE-MRI images were analysed with the software application 
DCE@urLAB. And DSC-MRI parametric maps were calculated using the ImageJ 
plugin LIMPERFUSION 1.0.0.  
The quantification and the results obtained with both programs have demonstrated that 
both protocols have been successfully optimized, and also it has been verified that a 
proper analysis of those can be achieved.  
In this project, DCE images were assessed by analysing the TIC (curve parameters 
method, semi-quantitative and non-model dependent) and by quantifying the contrast 
agent concentration changes using the pharmacokinetic model technique. Semi-
quantitative parameters were calculated due their simplicity of calculus. However, this 
analysis (curve parameters) presents some limitations like the inability to accurately 
reflect contrast agent concentration in the tissue of interest (tumor), can be influenced 
by scanner settings and do not directly inform on tissue physiology [8, 26]. So, to 
overpass these limitations quantitative parameters are analysed. In this project Hoffman 
model was selected because of its simplicity and high temporal resolution compared to 
other models (it does not require pre and post T1-w maps as Tofts model requires). 
The quantification analysis of the DSC-MRI images was developed to inform about 
tumor perfusion, since as was mentioned DSC-MRI technique is sensitive to the 
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presence of the contrast within the vascular space [24]. However, it should be 
mentioned that the information obtained with DSC quantification methods is relative, 
since absolute quantification of the DSC data is not currently possible. Thus, tracer 
kinetic principles can be used to provide estimates of relative blood volume (rBV), 
relative blood flow (rBF) and MTT [8].  
The differentiation of both DMRI techniques, such as the temporal resolution, the 
compartments studied and the complexity affects to the information obtained with each 
of them [8, 26]. In the case of DCE-MRI, the temporal resolution is lower (2-25 
seconds), then the contrast can be tracked in a longer term; and the compartments 
studied are two (EES and intravascular). Then, it can be said that the parameters 
acquired with this quantification are more related with tumor permeability information; 
concretely, the Akep pharmacokinetic parameter [50]) (Figure 27). Nevertheless, the 
characteristics of DSC-MRI technique (high temporal resolution, intravascular space 
studied, etc.) enable to provide information about the tumor perfusion (BV, BF and 
MTT parametric maps, Figure 30, Figure 31 and Figure 32 [24]). 
To determine the accuracy of the results obtained with DCE-MRI and DSC-MRI, and to 
evaluate if the information obtained from them is complementary or equivalent, 
histological proofs are required. Histological proofs would corroborate if the regions 
higher permeable coincide with the regions with higher kep value, and the same with the 
regions higher perfused and BV and BF parameters. Moreover, it would be determined 
the relation of DCE and DSC parameters, if permeable regions correspond to perfused 
regions. Finally, if both protocols were equivalent a single technique could be used to 
study tumor perfusion. Under this hypothesis the DSC-MRI protocol would be preferred 
due to its higher temporal resolution and its simpler process (compared to the DCE one) 
[8, 26].  
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Chapter 6 
Conclusions and future 
perspectives 
 
6.1 Conclusions 
In this work, two different approaches (DCE-MRI and DSC-MRI) to study the 
perfusion grade of subcutaneous 215 pancreatic tumors were tested and compared. MRI 
sequences and contrast doses were selected after a carefully review of the literature.  
For the optimization of DCE-MRI protocol two mice were used, in each of them a 
different dose was tested. Results obtained with the Dynamic Pixel Inspector plugin has 
established 0.05 mmol/kg body weight as the optimal contrast agent dose, and 0.12 ml 
as the optimal contrast media volume for the acquisition of a DCE image with high 
resolution, and without any contrast agent effects in T2 relaxivity time of the tissues.  
In the evaluation of DSC-MRI protocols, the same mouse was used in different 
acquisition days with two different concentrations of the contrast agent Results obtained 
with Dynamic Pixel Inspector plugin have determined 0.2 ml as the optimal contrast 
bolus volume for the acquisition of high resolution DSC images.  
Once the optimal protocols and their doses were determined, each of them was tested in 
the same mouse, with a day of difference to clean the contrast agent residues. Then, 
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images acquired with both approaches were analyzed. DCE data has been analyzed with 
the non-model dependent method curve parameters, and quantify with the Hoffman 
model; both analyzed with the DCE@urLAB program [50]. DSC images have been 
analyzed with the LIMPERFUSION 1.0.0 software [57]. Both protocols were 
successfully analyzed and the results obtained provide good indicators of tumor 
perfusion [46, 50].  
 
 
6.2 Future perspectives 
There exists a wide range of future approaches to continue with this project. 
As it was mentioned before, a histology analysis could be highly advantageous to 
compare and evaluate both DMRI techniques. The quantitative parameters obtained 
with both techniques give information about the morphology of tumors, indicating those 
regions higher vascularized and those more necrotic; this information would be 
confirmed or disproved based on histological studies.  
Another approach would be to evaluate the DCE quantification with other model. 
Hoffman model was selected because of its simplicity. However, this model could have 
some  limitations, since the information obtained about the tumor physiology is less 
specific than the one obtained with other methods; as for example the Tofts model; 
which is the most widely used in measuring vessel permeability [24]. Tofts model 
requires the acquisition of pre-contrast and post-contrast T1 maps. If the data required 
for both Hoffman and Tofts is acquired and both models analysed, the histology data 
would be also useful to evaluate the advantages and disadvantages of each model [49, 
52].   
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